Improved chemotherapy modeling with RAG-based immune deficient mice.

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Current severe combined immune deficiency (SCID)-based mouse models for acute myeloid leukemia (AML) chemotherapy have limitations.
• These limitations include inability to combine preconditioning with chemotherapy, repeat cycles, and host cell sensitivity to genotoxic stress.

Purpose of the Study:

• To evaluate RAG-based immune deficient mice as an improved model for AML and acute lymphoid leukemia (ALL) chemotherapy.
• To overcome limitations of SCID-based models for preclinical therapeutic evaluations.

Main Methods:

• Comparison of RAG-based (NRG, NRGS) and SCID-based (NSG, NSGS) mouse models.
• Administration of cytarabine (AraC) and anthracycline chemotherapy regimens.
• Inclusion of busulfan preconditioning in RAG-based models.
• Evaluation of chemotherapy specificity and tolerance to multiple cycles.

Main Results:

• RAG-based mice tolerate busulfan preconditioning combined with AML or ALL chemotherapy.
• RAG-based mice tolerate multiple cycles of chemotherapy, enabling more aggressive and realistic modeling.
• Standard AML therapy demonstrated 3.8-fold greater specificity for AML cells in RAG mice compared to SCID mice, indicating an improved therapeutic window.

Conclusions:

• RAG-based immune deficient mice represent a superior model for preclinical evaluation of therapeutic strategies involving genotoxic agents.
• These mice overcome key limitations of SCID-based models, allowing for more comprehensive and accurate research in leukemia chemotherapy.